Table 2 Primary and secondary endpoints
From: Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
| Â | Entire Cohort | Non-SGLT2i | SGLT2i | p value |
|---|---|---|---|---|
All-cause Mortality, N (%) | 61 (51) | 56 (59) | 5 (21) | 0.002 |
Progression, N (%) | 96 (81) | 78 (82) | 18 (75) | 0.431 |
MACE, N (%) | 16 (13) | 12 (13) | 4 (17) | 0.855 |
Arrhythmia Composite, N (%) | 6 (5) | 6 (6) | 0 (0) | 0.458 |
Av block, N (%) | 1 (1) | 1 (1) | 0 (0) | 1.000 |
Atrial fibrillation, N (%) | 6 (5) | 6 (6) | 0 (0) | 0.458 |
Acute Coronary Syndrome, N (%) | 6 (5) | 5 (5) | 1 (4) | 1.000 |
Myocarditis, N (%) | 2 (2) | 2 (2) | 0 (0) | 1.000 |
Heart Failure admissions, N (%) | 2 (2) | 1 (1) | 1 (4) | 0.864 |
Heart Failure exacerbations, N (%) | 7 (6) | 5 (5) | 2 (8) | 0.932 |